Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1996-10-04
1999-09-21
Duffy, Patricia A.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
435 792, 436503, 436518, 436811, G01N 3353
Patent
active
059552859
ABSTRACT:
Dense microspheres can be extracted and purified to substantial homogeneity from mammalian brain tissue, and used in the screening of therapies for potential effectiveness in impeding the formation of amyloid fibrils associated with Alzheimer's disease and other forms of cerebral amyloidosis. Compounds that, at in-tissue concentrations of 10.sup.-5 M or less, inhibit amyloid formation in a test animal injected intracerebrally with dense microspheres are particularly useful in inhibiting treating cerebral amyloidosis.
REFERENCES:
patent: 4267271 (1981-05-01), Roberts
patent: 4316895 (1982-02-01), Kimball et al.
patent: 4448779 (1984-05-01), Blanchard et al.
patent: 4550109 (1985-10-01), Flokers et al.
patent: 4578394 (1986-03-01), Allen et al.
patent: 4605652 (1986-08-01), Welstead
patent: 4666829 (1987-05-01), Glenner et al.
patent: 4816416 (1989-03-01), Averback
patent: 4919915 (1990-04-01), Averback
patent: 5100645 (1992-03-01), Ali-Khan et al.
patent: 5231170 (1993-07-01), Averback
patent: 5525339 (1996-06-01), Averback
patent: 5567720 (1996-10-01), Averback
Strittmatter et al, Proc. Natl. Acad. Sci, 90:1977-1981, Mar. 1993.
Chung et al, Life Sci, 47(13):1163-1170, 1990.
vanGool et al, JACS 1 39:1025-1031-1991.
Hara, M., J. Neuropathol Exp. Neurol: 45(2):169-178, 1986.
George et al, ACTA Neuropathol, 86(1):86-89, 1993.
Averback, Medline abstract of Acta Neuropathol, vol. 61, No. 2, pp. 148-152, 1983.
Averback, Immunofluorescent Staining of Dense Microspheres in Human Brain, Arch Pathol Lab. Med., vol. 106:394 (1982).
Averback, The Dense Microsphere: A Newly Delineated Origin of the Senile Plague in Human Brain, The Canadian Journal of Neurological Sciences, 284 May 1982.
Averback, Ultrastructural Studies of the Origin and Growth of Dense Micro-spheres in Normal Human Brain, The Canadian Journal of Neurological Sciences, 290, May 1982.
Averback, Morphometric and Anatomical Correlation of Dense Microsphere and Senile Plague Formation in Alzheimer's Disease, Lejournal Canadien Des Sciences Neurologiques, 283, May 1982.
Averback, Quantitative Correlations of Dense Microspheres and Senile Plagues in Alzheimer Disease, Neurology 32(2) May 1982.
Averback, Population, Distribution, and Growth of Dense Miceospheres in the Human, Federation Proceedings, vol. 41, Mar. 1982.
Averback, Acta Neuropathol. 61: 148-152 1983.
Hara, J. Neuropath, Exp. Neurol 1986.
Selkoe et al., Science 235: 873, 1987.
Graves & Kickhan, New England J. Med. 214: 782-783, 1936.
Wallance, The Lancet, Feb. 20, 1932, at 391-393.
Kennet et al., Curr. Top. Microbiol., Immunol. 81: 77-91 1978.
Wisniewski et al. J. Neuropathol & Exp. Neurol 32:566, 1973.
Averback, et al. Unusual Particles in Motor Neurodisease, Arch. Pathol Lab. Med. vol. 105(9) 490-3, Sep. 1981.
Kipps et al., Schemata for the Prod. of Monoclonal Antibody Producing Hybridomes Chapter 108 Handbook of Exp. Immunology pp. 108.1-108.9 Blackwell Sci. Pub. London, 1967.
Ward et al., Binding ACtivites of a Repertoire of Single Immunoglobulin Variable Domains Secreted from Escherichia Coli; Nature 341:544-546 (1989), p. 24, lines 21-22.
Gillies et al., Biotechnol. 7:799-804 91989), p. 24, lines 23-24.
Natakani et al. Biotechnol 7:805-810 (1989), p. 24, lines 24-25.
Huse et al. Generation of a Large Combination Library of the Immonoglobulin Repertoire in Phage Lambda; Science 246:1275-1281 (1989), p. 25, lines 1-2.
Averback New Brain Particles and Nervous Disease; Can. J. Neurological Sci. (conf.) p. 187, (1981).
Gaskin et al. Autoantibodies to Neurofibrillary Tangles and Brain Tissue in Alzheimer's Disease J. Exp. Med. 165:245-250 (Jan. 1987).
Duffy Patricia A.
Nymox Pharmaceutical Corporation
LandOfFree
Method of identifying individuals at risk of suffering from cere does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of identifying individuals at risk of suffering from cere, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of identifying individuals at risk of suffering from cere will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-79046